ReviewInternational journal of molecular medicine2025
Current status of severe fever with thrombocytopenia syndrome in China (Review).
Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of different therapies on invasive pulmonary aspergillosis in patients with severe fever and thrombocytopenia syndrome: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- SFTSV-encoded microRNA-like small RNA as prognostic biomarkers in severe fever with thrombocytopenia syndrome.Emerging microbes & infections · 2026Article
- A potent Gc neutralizing antibody reveals architecture-dependent bispecific protection against SFTSV.Emerging microbes & infections · 2026Article
- Establishment and application of a multiplex qPCR panel for multi-host surveillance of tick-Borne pathogens.Emerging microbes & infections · 2026Article
- Genotype-Specific Amino Acid Signatures in the Gn/Gc Glycoprotein of Severe Fever with Thrombocytopenia Syndrome Virus Associated with Neurological Symptoms.Pathogens (Basel, Switzerland) · 2026Article
- Effectiveness of lignans against severe fever with thrombocytopenia syndrome virus infection.Virologica Sinica · 2026Article
- Epidemiological characteristics of severe fever with thrombocytopenia syndrome (SFTS) in China, 2010-2024: a fifteen-year national surveillance analysis.BMC infectious diseases · 2026Article
- Immunopathogenesis of Severe Fever with Thrombocytopenia Syndrome: Core Driving Role of Cytokine Storm.Current issues in molecular biology · 2026Review
- SFTSV: a priority pathogen in need of a cure-reviewing the therapeutic.Archives of microbiology · 2026Review
- Prevalence and Diversity of Severe Fever with Thrombocytopenia Syndrome Virus and Co-Infection withPathogens (Basel, Switzerland) · 2026Article
- A novel scoring system for precise severity quantification in severe fever with thrombocytopenia syndrome: development and application based on dynamic clinical data.Frontiers in microbiology · 2026Article
- Article
- Multidimensional mechanisms of SFTSV-host interactions: viral protein functions, mFrontiers in cellular and infection microbiology · 2026Review
- Clinical outcomes and safety of tocilizumab in severe fever with thrombocytopenia syndrome: a retrospective multicenter cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Development and Validation of a Novel Predictive Model and Simplified Clinical Indicator for Mortality in Severe Fever with Thrombocytopenia Syndrome Patients.Infection and drug resistance · 2026Article
- Research progress on emerging and important Tick-Borne pathogens.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerging tick‑borne infectious disease caused by the novel Bunyavirus/SFTS virus (SFTSV). The clinical manifestations mainly include fever, thrombocytopenia and multi‑organ dysfunction, with a fatality rate as high as 30%. Since its first report in China in 2009, cases have subsequently emerged in multiple countries across East and Southeast Asia. SFTS demonstrates clear seasonal trends from May to November and tends to cluster geographically, mainly in hilly and mountainous areas. The virus is transmitted through tick bites, animal contact and human‑to‑human transmission. Its genetic diversity and frequent genetic recombination exacerbate public health threats. Pathogenic mechanism studies have shown that SFTSV uses glycoproteins Gn/Gc to mediate host cell invasion. In the early stage, the virus uses its non‑structural protein NSs to inhibit innate immune signal transduction. Massive replication of the virus leads to excessive immune activation, triggering cytokine storms and abnormal platelet activation, and eventually resulting in bleeding and multiple organ failure. The clinical management primarily relies on supportive care, while broad‑spectrum antiviral drugs and neutralizing antibodies remain investigational. Although numerous vaccine candidates have been designed and developed, none have progressed to clinical trials. This review systematically integrates current knowledge spanning virology, epidemiology, pathogenic mechanisms, therapeutic interventions and vaccine development, offering actionable insights for public health strategies and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.